A well-supplied UK & EU sector, led by PRINTING HOUSE LTD, most recent listing 9 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
The Techniker Krankenkasse (TK) aims to establish discount contracts with all suitable pharmaceutical companies for the active ingredient Abemaciclib, in accordance with § 130c Abs. 1 SGB V. This contract will be part of TK's Open House Original procedure, where individual negotiations on contract t
IKK classic is announcing that it will enter into non-exclusive discount agreements with interested and qualified pharmaceutical companies for various active ingredients and combinations of active ingredients. These agreements will be based on fixed, non-negotiable terms in accordance with § 130a Ab
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the medication Clobetasol, specifically in foam form (ATC D07AD01). This agreement is part of a framework established under § 130a Abs. 8 SGB V, which allows health insurance companies and pharmaceutical fir
This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Abiraterone, specifically in the 500mg strength and 90 tablet pack size. Under § 130a Abs. 8 SGB V, health insurance funds and pharmaceutical companies can enter into framework di
The KKH (Kaufmännische Krankenkasse) aims to establish non-exclusive discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a Abs. 8 SGB V. This process will provide uniform contract conditions and access procedu
This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Rivaroxaban (ATC: B01AF01 - in all strengths except 2.5 mg per divided oral dosage form) under an 'open-house model'. All eligible and interested ph
This contract opportunity involves establishing non-exclusive discount agreements for pharmaceuticals containing the active ingredients Brinzolamid and Brimonidin (official ATC code: S01EC24) under the German Social Code. The agreements will be made through an Open-House model, allowing all interest
This contract opportunity involves establishing non-exclusive discount agreements for the medication Certolizumab pegol, as per § 130a Abs. 8 SGB V. The agreements will be made under an Open-House model, allowing all interested pharmaceutical companies to participate during the application period, p
This contract opportunity involves the establishment of non-exclusive discount contracts for the medication Rivaroxaban, specifically for film-coated tablets excluding the 2.5 mg strength. The contracts will be in effect from October 1, 2025, to September 30, 2027, with the option for suppliers to e
The German health insurance companies and pharmaceutical companies can enter into framework discount agreements for medications covered by statutory health insurance, as permitted by § 130a paragraph 8 of the Social Code Book V. The DAK-Gesundheit will conduct a formal procurement process for the ac
